Circulating tumor cells on the go with Biocept IPO
This article was originally published in Clinica
Executive Summary
Another diagnostics company, Biocept Laboratories, is taking its chances on the public market. The San Diego, California company specializes in biomarker analysis and measurement of circulating tumor cells (CTCs), which could be used for the diagnosis, prognosis and monitoring of cancer. It is hoping to raise up to $23m, according to its filing with the US Securities and Exchange Commission (SEC) – but did not say how many shares it plans to sell or their price. Biocept will list on the Nasdaq market under the ticker symbol BIOC.